Droperidol
| Code | Size | Price |
|---|
| CDX-D0823-G001 | 1 g | £108.00 |
Quantity:
| CDX-D0823-G005 | 5 g | £407.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
1-[1-[3-(p-Fluorobenzoyl)propyl]-1,2,3,6-tetrahydro-4-pyridyl]-2-benzimidazolinone; NSC 169874
Appearance:
White to light yellow powder.
CAS:
548-73-2
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Protect from light and moisture.
Hazards:
H302
InChi:
InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)
InChiKey:
RMEDXOLNCUSCGS-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 548-73-2. Formula: C22H22FN3O2. MW: 379.43. Droperidol is a butyrophenone that acts as an antagonist at dopamine receptors D2 and D4. It less potently inhibits the human voltage-gated potassium channel, 5-HT, alpha-adrenergic and histamine receptors. Droperidol has been shown to provide relief from acute migraines and prevent nausea and vomiting in clinical trials and has anti-psychotic activity.
MDL:
MFCD00083290
Molecular Formula:
C22H22FN3O2
Molecular Weight:
379.43
Package Type:
Vial
Precautions:
P301 + P312 + P330
Product Description:
Droperidol is a butyrophenone that acts as an antagonist at dopamine receptors D2 and D4. It less potently inhibits the human voltage-gated potassium channel, 5-HT, alpha-adrenergic and histamine receptors. Droperidol has been shown to provide relief from acute migraines and prevent nausea and vomiting in clinical trials and has anti-psychotic activity.
Purity:
>98% (TLC)
SMILES:
O=C(C1=CC=C(F)C=C1)CCCN2CCC(N3C4=CC=CC=C4NC3=O)=CC2
Solubility Chemicals:
Soluble in DMSO (20mg/ml) or DMF (20mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
References
(1) S.J. Peroutka & S.H. Synder; Am. J. Psychiatry 137, 1518 (1980) | (2) R. Rajamani, et al.; Bioorg. Med. chem. Lett. 15, 1737 (2005) | (3) J.R. Richards, et al.; J. Emerg. Med. 41, 389 (2011) (Review) | (4) J.D. Griffiths, et al.; Cochrane Database Syst.Rev. 9, 1 (2012) | (5) M.C. Thomas, et al.; Ann. Pharmacother. 49, 233 (2015) (Review) | (6) P. Seeman & T. Tallerico; Mol. Psych. 3, 123 (2016)